CoChat

Minimizing the Inhibitory Effect of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated Virus 8 Vectors

Open access
Mimuro, Jun, Mizukami, Hiroaki, Hishikawa, Shuji, Ikemoto, Tomokazu, Ishiwata, Akira, Sakata, Asuka, Ohmori, Tsukasa, Madoiwa, Seiji, Ono, Fumiko, Ozawa, Keiya, Sakata, Yoichi · 2013 · Molecular Therapy
Cited by 74

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) are known to interfere with AAV vector-mediated gene transfer by intravascular delivery. Evading the inhibitory effects of antibodies against AAV vectors is necessary for efficient transfer of therapeutic genes clinically. For this purpose, we tested the efficacy of saline flushing in order to avoid contact of vectors with NAbs present in blood. Direct injection of the AAV8 vector carrying the factor IX (FIX) gene into the portal vein of macaques using saline flushing achieved transgene-derived FIX expression (4.7 ± 2.10-10.1 ± 5.45% of normal human FIX concentration) in the presence of NAbs. Expression was as efficient as that (5.43 ± 2.59-12.68 ± 4.83%) in macaques lacking NAbs. We next tested the efficacy of saline flushing using less invasive balloon catheter-guided injection. This approach also resulted in efficient expression of transgene-derived FIX (2.5 ± 1.06-9.0 ± 2.37%) in the presence of NAbs (14-56× dilutions). NAbs at this range of titers reduced the efficiency of transduction in the macaque liver by 100-fold when the same vector was injected into mesenteric veins without balloon catheters. Our results suggest that portal vein-directed vector delivery strategies with flushing to remove blood are efficacious for minimizing the inhibitory effect of anti-AAV antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2012.258

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Pasi, 2001, Gene therapy for haemophilia, Br J Haematol, 115, 744, 10.1046/j.1365-2141.2001.03225.x · DOI
  2. VandenDriessche, 2003, Gene therapy for the hemophilias, J Thromb Haemost, 1, 1550, 10.1046/j.1538-7836.2003.00265.x · DOI
  3. Chuah, 2004, Preclinical and clinical gene therapy for haemophilia, Haemophilia, 10, 119, 10.1111/j.1365-2516.2004.00984.x · DOI
  4. Chuah, 2004, Clinical gene transfer studies for hemophilia A, Semin Thromb Hemost, 30, 249, 10.1055/s-2004-825638 · DOI · Paper page
  5. Hasbrouck, 2008, AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects, Gene Ther, 15, 870, 10.1038/gt.2008.71 · DOI
  6. Kay, 2000, Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector, Nat Genet, 24, 257, 10.1038/73464 · DOI · Paper page
  7. Jiang, 2006, Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B, Mol Ther, 14, 452, 10.1016/j.ymthe.2006.05.004 · DOI · Paper page
  8. Nathwani, 2002, Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques, Blood, 100, 1662, 10.1182/blood-2002-02-0589 · DOI · Paper page
  9. Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
  10. Nathwani, 2007, Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates, Blood, 109, 1414, 10.1182/blood-2006-03-010181 · DOI · Paper page
  11. Ishiwata, 2010, Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques, Thromb Res, 125, 533, 10.1016/j.thromres.2010.01.049 · DOI
  12. Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J Infect Dis, 199, 381, 10.1086/595830 · DOI · Paper page
  13. Lautt, 1987, Conceptual review of the hepatic vascular bed, Hepatology, 7, 952, 10.1002/hep.1840070527 · doi:10.1002/hep.1840070527
  14. High, 2007, Update on progress and hurdles in novel genetic therapies for hemophilia, Hematology Am Soc Hematol Educ Program, 466, 10.1182/asheducation-2007.1.466 · DOI
  15. Sands, 2011, AAV-mediated liver-directed gene therapy, Methods Mol Biol, 807, 141, 10.1007/978-1-61779-370-7_6 · DOI · Paper page
  16. Hurlbut, 2010, Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy, Mol Ther, 18, 1983, 10.1038/mt.2010.175 · DOI · Paper page
  17. Li, 2012, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 19, 288, 10.1038/gt.2011.90 · DOI · Paper page
  18. Chandler, 2011, A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates, Mol Ther, 19, 826, 10.1038/mt.2011.73 · DOI
  19. Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
  20. Muir, 1975, Cardiorespiratory effects of rapid saline infusion in normal man, J Appl Physiol, 38, 775, 10.1152/jappl.1975.38.5.786 · doi:10.1152/jappl.1975.38.5.786
  21. Urata, 1995, Calculation of child and adult standard liver volume for liver transplantation, Hepatology, 21, 1317, 10.1002/hep.1840210515 · DOI · Paper page
  22. Greenway, 1974, Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized cats, J Physiol (Lond), 237, 279, 10.1113/jphysiol.1974.sp010482 · DOI
  23. Lautt, 1976, Hepatic venous compliance and role of liver as a blood reservoir, Am J Physiol, 231, 292, 10.1152/ajplegacy.1976.231.2.292 · doi:10.1152/ajplegacy.1976.231.2.292
  24. Mimuro, 2004, Specific detection of human coagulation factor IX in cynomolgus macaques, J Thromb Haemost, 2, 275, 10.1046/j.1538-7933.2003.00572.x · DOI
  25. Mohammadi, 2004, Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line, Nucleic Acids Res, 32, 2652, 10.1093/nar/gkh593 · DOI

Cited by

See all 74

Metadata

Authors
Mimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., & Sakata, Y.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2013-02
Volume
21
Issue
2
Pages
318-323
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2039881052
Cited by
74
References
10
FWCI
4.25
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • Ministry of Health, Labour and Welfare

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.